Skip to content

Reimagining Neuroscience Drug Discovery

February 2025 Update

Phrenix Therapeutics is pleased to announce the successful close of our seed funding round, backed by leading venture capital firms Curie.Bio and Brandon Capital.

This investment accelerates our pipeline towards the clinic, advancing highly targeted therapeutics for cognitive, psychiatric, and neurological conditions and bringing us closer to transforming the lives of individuals, families, and communities.

We’re excited to start the next phase of our company’s journey and look forward to working with our new partners to drive meaningful advances in neuroscience drug discovery.

Read more here.

Phrenix Therapeutics - NDC LAB 2

Our Pipeline

Discovery driven by lived experience

“I wish to declare us the curators of our own psyches”
Sandy Jeffs OAM, Poem 32 from The Madhouse (2002)

Enhanced drug discovery

Using structure-guided design and disease-relevant analytical pharmacology, we are developing a pipeline of G protein-coupled receptor (GPCR) targeted therapeutics for psychiatric and neurological disorders.

Reimagining translation in psychiatry

We use rodent touchscreen-based technologies to evaluate targets and assess pro-cognitive compound efficacy. Unlike much psychiatry R&D in the past 50 years, our testing reflects clinical outcomes.

Back To Top